Lupin Q2 results preview: Strong earnings growth to be led by new launches in the US, improving domestic sales
Q2 Result Preview- Launch of limited competition opportunities like- generic Spiriva, generic of Prezista and Suprep kit under exclusivity along with improving domestic sales could leading to a 3-fold jump in earnings during Q2 as per PhillipCapital Institutional Equity Research.
DNA News Desk
0
7
Q2 Result Preview- Launch of limited competition opportunities like- generic Spiriva, generic of Prezista and Suprep kit under exclusivity along with improving domestic sales could leading to a 3-fold jump in earnings during Q2 as per PhillipCapital Institutional Equity Research.
